Unlocking CAR T-cell therapy for solid tumours
Currus Biologics is developing its proprietary BEAT technology for solid tumours
CAR T-cell therapy is a personalised immunotherapy which works by extracting and genetically engineering a patient’s T-cells to produce chimeric antigen receptors (CARs). After infusion back into the patient, these CARs allow T-cells to seek out and destroy specific cancer cells.
The BEAT platform unlocks CAR T-cell therapy for solid tumours – approximately 90% of the oncology market, which has remained largely impervious to treatment with current CAR T-cell approaches.
Currus Biologics’ BEAT recreates the immune-supportive conditions in which CAR T-cells already succeed in liquid tumours, directly addressing the biological barriers – poor proliferation and persistence, T-cell exhaustion, and limited tumour infiltration – that have held CAR T-cell therapy back in solid tumours.
